Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.039 AUD | 0.00% | +8.33% | -47.30% |
05-08 | Radiopharm Theranostics to be Featured in Healthcare Events Hosted by B. Riley Securities | MT |
02-29 | Radiopharm Theranostics Doses First Patient in Pancreatic Cancer Imaging Study | MT |
Valuation
Fiscal Period: June | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|
Capitalization 1 | 26.42 | 23.73 | 11.64 | - | - |
Enterprise Value (EV) 1 | 26.42 | 23.73 | 16.92 | 15.6 | 14.94 |
P/E ratio | -0.9 x | -0.95 x | -0.37 x | -0.37 x | -0.39 x |
Yield | - | - | - | - | - |
Capitalization / Revenue | - | 125 x | - | - | - |
EV / Revenue | - | 125 x | - | - | - |
EV / EBITDA | -2.14 x | -1.17 x | -0.6 x | -0.48 x | -0.41 x |
EV / FCF | - | -1,481,782 x | - | - | - |
FCF Yield | - | -0% | - | - | - |
Price to Book | - | 0.83 x | - | - | - |
Nbr of stocks (in thousands) | 255,433 | 339,313 | 451,796 | - | - |
Reference price 2 | 0.1034 | 0.0699 | 0.0258 | 0.0258 | 0.0258 |
Announcement Date | 30/08/22 | 31/08/23 | - | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: June | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|
Net sales 1 | - | - | 0.1893 | - | - | - |
EBITDA 1 | - | -12.36 | -20.19 | -28.29 | -32.65 | -36.46 |
EBIT 1 | - | -14.42 | -22.33 | -29.03 | -31.78 | -37.01 |
Operating Margin | - | - | -11,796.17% | - | - | - |
Earnings before Tax (EBT) 1 | - | -20.85 | -22.38 | -29.01 | -31.76 | -37 |
Net income 1 | -0.3503 | -20.88 | -22.41 | -29.01 | -31.76 | -37 |
Net margin | - | - | -11,838.62% | - | - | - |
EPS 2 | - | -0.1152 | -0.0733 | -0.0695 | -0.0695 | -0.0660 |
Free Cash Flow | - | - | -16.01 | - | - | - |
FCF margin | - | - | -8,459.64% | - | - | - |
FCF Conversion (EBITDA) | - | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - | - |
Dividend per Share | - | - | - | - | - | - |
Announcement Date | 23/11/21 | 30/08/22 | 31/08/23 | - | - | - |
Income Statement Evolution (Quarterly data)
Fiscal Period: June | 2023 Q1 | 2023 Q2 | 2023 S1 | 2023 S2 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 | 2025 Q3 |
---|---|---|---|---|---|---|---|---|---|---|
Net sales 1 | 0.1013 | 0.0945 | 0.1974 | - | - | - | - | - | - | - |
EBITDA | - | - | - | - | - | - | - | - | - | - |
EBIT | - | - | - | -14.55 | - | - | - | - | - | - |
Operating Margin | - | - | - | - | - | - | - | - | - | - |
Earnings before Tax (EBT) | - | - | - | - | - | - | - | - | - | - |
Net income | - | - | -8.476 | -14.28 | - | - | - | - | - | - |
Net margin | - | - | -4,293.45% | - | - | - | - | - | - | - |
EPS | - | - | -0.0307 | - | - | - | - | - | - | - |
Dividend per Share | - | - | - | - | - | - | - | - | - | - |
Announcement Date | 28/11/22 | 28/02/23 | 28/02/23 | 31/08/23 | 29/02/24 | - | - | - | - | - |
Balance Sheet Analysis
Fiscal Period: June | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|
Net Debt 1 | - | - | - | 5.28 | 3.96 | 3.3 |
Net Cash position 1 | - | - | - | - | - | - |
Leverage (Debt/EBITDA) | - | - | - | -0.1865 x | -0.1212 x | -0.0905 x |
Free Cash Flow | - | - | -16 | - | - | - |
ROE (net income / shareholders' equity) | - | - | - | -120% | -127% | -132% |
ROA (Net income/ Total Assets) | - | - | - | -64.5% | -70.7% | -75.2% |
Assets 1 | - | - | - | 44.98 | 44.93 | 49.21 |
Book Value Per Share | - | - | 0.0800 | - | - | - |
Cash Flow per Share | - | - | - | - | - | - |
Capex 1 | - | - | 0.99 | 0.03 | 0.03 | 0.03 |
Capex / Sales | - | - | 523.56% | - | - | - |
Announcement Date | 23/11/21 | 30/08/22 | 31/08/23 | - | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
EPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-47.30% | 11.29M | |
+32.36% | 698B | |
+26.51% | 568B | |
-4.40% | 358B | |
+19.46% | 328B | |
+3.50% | 283B | |
+16.34% | 238B | |
+6.68% | 203B | |
-9.08% | 198B | |
+8.62% | 165B |
- Stock Market
- Equities
- RAD Stock
- Financials Radiopharm Theranostics Limited